登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
ClinicalTrials.gov 上登记的一项胃癌开放试验,由空军军医大学西京医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07685704,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically and radiologically (CT/MRI) confirmed gastric or gastroesophageal junction adenocarcinoma.
入选标准第 2 条
Neoadjuvant cohort: Clinical stage III (cT3-4aN+M0) or locally advanced unresectable (cT4bNany M0) assessed by MDT as not amenable to R0 resection, or technically resectable but with high-risk factors (e.g., bulky nodal fusion, invasion of critical structures).
入选标准第 3 条
ECOG performance status 0-1; no contraindication to surgery.
入选标准第 7 条
WBC > 4.0 x 10\^9/L and < 15 x 10\^9/L; ANC > 1.5 x 10\^9/L; Hb >= 90 g/L; PLT >= 100 x 10\^9/L.
入选标准第 11 条
Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN.
入选标准第 12 条
Creatinine <= 1.5 x ULN, or CrCl > 60 mL/min (Cockcroft-Gault).
入选标准第 13 条
No anticoagulation: INR and aPTT <= 1.5 x ULN. On stable anticoagulation: maintain stable dose.
入选标准第 14 条
History of malignancy within 5 years before screening, except those with > 90% 5-year overall survival.
排除标准第 3 条
Active hepatitis B (HBV DNA >= 1 x 10\^3 copies/mL or >= 200 IU/mL), positive anti-HCV, or positive HIV.
排除标准第 13 条
Female patients of childbearing potential must agree to contraception from ICF signing through at least 5 months after last dose and refrain from breastfeeding. Male patients must agree to contraception from first dose through at least 7 months after last dose.
入选标准第 16 条
Pregnancy or breastfeeding, or planning pregnancy during the study.
排除标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07685704,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Willing and able to provide written informed consent (ICF). Histologically and radiologically (CT/MRI) confirmed gastric or gastroesophageal junction adenocarcinoma. Neoadjuvant cohort: Clinical stage III (cT3-4aN+M0) or locally advanced unresectable (cT4bNany M0) assessed by MDT as not amenable to R0 resection, or technically resectable but with high-risk factors (e.g., bulky nodal fusion, invasion of critical structures). Conversion cohort: Not amenable to direct surgery (e.g., invasion of adjacent organs or vessels) or with distant metastases, including liver metastases (C-GCLM type I and II), confirmed retroperitoneal lymph node metastases, or other single-organ metastases. HER2-positive by IHC (3+; or 2+ with FISH testing). No time window restriction on FISH. Age 18-75 years, male or female. ECOG performance status 0-1; no contraindication to surgery. Adequate organ function for successful abdominal surgery. Life expectancy >= 3 months. Laboratory parameters within 7 days before enrollment: WBC > 4.0 x 10\^9/L and < 15 x 10\^9/L; ANC > 1.5 x 10\^9/L; Hb >= 90 g/L; PLT >= 100 x 10\^9/L. Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN. Creatinine <= 1.5 x ULN, or CrCl > 60 mL/min (Cockcroft-Gault). No anticoagulation: INR and aPTT <= 1.5 x ULN. On stable anticoagulation: maintain stable dose. Good compliance; able to complete protocol-specified examinations and specimen collection. Female patients of childbearing potential must agree to contraception from ICF signing through at least 5 months after last dose and refrain from breastfeeding. Male patients must agree to contraception from first dose through at least 7 months after last dose.排除标准:Exclusion Criteria:
Synchronous or metachronous malignancies of other organs, or recurrent disease. Prior systemic therapy for gastric cancer (neoadjuvant cohort). History of malignancy within 5 years before screening, except those with > 90% 5-year overall survival. Significant cardiopulmonary dysfunction. Major surgery within 4 weeks before study treatment initiation, or anticipated major surgery during study period (excluding diagnostic procedures). Severe infection within 4 weeks before study treatment initiation. Prior chemotherapy or molecular targeted therapy (neoadjuvant cohort). Known hypersensitivity to study drugs or excipients, or history of severe allergic reactions to monoclonal antibodies. Factors affecting oral medication intake (e.g., dysphagia >= grade 2, chronic diarrhea). Significant uncontrolled comorbidities that may affect protocol compliance or interpretation of outcomes. Pregnancy or breastfeeding, or planning pregnancy during the study. Diagnosis of immunodeficiency or receiving systemic corticosteroid (> 10 mg/day prednisone equivalent) or other immunosuppressive therapy within 2 weeks before first dose. Active hepatitis B (HBV DNA >= 1 x 10\^3 copies/mL or >= 200 IU/mL), positive anti-HCV, or positive HIV. Participation in another anti-tumor clinical trial within 28 days before first dose. Any condition that in the investigator's judgment may lead to premature study termination (e.g., serious illness including psychiatric disorders requiring concomitant treatment, severe laboratory abnormalities, family/social factors affecting subject safety or data collection). Patient or family refusal to sign informed consent.
引自 ClinicalTrials.gov, NCT07685704, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07685704,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。